Fintel reports that on January 10, 2025, Cantor Fitzgerald initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a Overweight recommendation. Analyst Price Forecast Suggests 77.07% ...
Some results have been hidden because they may be inaccessible to you